HLA-A and glioblastoma: As a result of the frequent overexpression of the selected TAAs and the restriction to HLA-A*02:01-positive patients, a high percentage of eligible GBM patients will have tumours presenting CVGBM-encoded epitopes of multiple TAAs, which might increase efficacy of the immunotherapeutic and reduce the risk of immune evasion by antigen loss.